罗格列酮对2型糖尿病合并稳定型心绞痛血脂水平的影响

目的探讨罗格列酮对2型糖尿病合并稳定型心绞痛病人血脂水平的影响。方法2型糖尿病合并稳定型心绞痛病人58例，随机分人对照组和罗格列酮组。对照组采用原来降血糖药和冠心病二级预防药作常规治疗，不加用罗格列酮。罗格列酮组在原来降血糖药的基础上给予罗格列酮4mg口服，每日1次，共30日。治疗前后分别测定血清总胆固醇，甘油三酯，高密度脂蛋白胆固醇和低密度脂蛋白胆固醇水平。结果治疗30日后，两治疗组血脂水平血清总胆固醇，甘油三酯，低密度脂蛋白胆固醇，载脂蛋白A和载脂蛋白B均有不同程度的下降，高密度脂蛋白胆固醇升高，但两组的改变程度差异有统计学意义（P〈0．05）。结论罗格列酮在常规治疗的基础上可以使血脂水平进一步改善，使2型糖尿病合并稳定型心绞痛病人受益。

Effect of rosiglitazone on plasma lipid levels in patients with type 2 diabetes and stable angina pectoris

Objectives To evaluate the therapeutic efficacy of rosiglitazone on plasma lipid levels in patients with stable angina pectoris and type 2 diabetes. Methods A total of 58 diabetic patients with stable angina were divided into two groups randomly: control group A and rosiglitazone therapy group(B) from May 2004 to June 2005. Patients in group B were received a stabilization,30 days therapy with rosiglitazone ,4mg daily. But the control group was received traditional drugs to type 2 DM and secondary prevention of coronary artery disease. The serum levels of total cholesterol(TC),TG, HDL-C,LDL-C were detected before and after therapy. Results 30 days later,the levels of TC,TG,LDL-C decreased significantly and the decreasing(TC,TG,LDL-C) and increasing(HDL-C)degree had statistical differences between two groups(P<0.05). Conclusions Rosiglitazone can improve plasma lipid levels and benefit the patients with type 2 diabetes and stable angina pectoris.